Treatment of multiple sclerosis

Details Treatment of multiple sclerosis Treatment of multiple sclerosis

1994-10-21

1997-09-30

Raymond, Richard L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514258, 514392, 548543, A61K 3140

Patent

active

056726228

ABSTRACT:
The present invention is a method of preventing or ameliorating the episodic recurrence of MS, comprising administering an effective amount of selective phosphodiesterase inhibitors of Type IV, e.g., Rolipram, e.g., wherein the severity of the episodic recurrences is ameliorated or the time period between episodes is lengthened.

REFERENCES:
patent: 4153713 (1979-05-01), Huth et al.
patent: 4943573 (1993-09-01), Meanwell et al.
patent: 5227369 (1993-07-01), Rosen et al.
patent: 5420154 (1995-05-01), Christansen IV et al.
patent: 5541219 (1996-07-01), Fenton et al.
"Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes", C.D. Nicholson et al., TiPS, vol. 12, Jan. 1991.
"Inhibition of Eosinophil Oxygen Radical Production by Type IV--But Not Type III--Selective cAMP Phosphodiesterase Inhibitors", G. Dent et al., Br. J. Pharm., vol. 22, (163P), 1990.
"Demyelinating Diseases", Cecil Textbook of Medicine, Wyngaarden et al., eds., 19th ed., 1992, pp. 2199-2200.
"Pentoxifylline inhibits experimental allergic encephalomyelitis", S, Nataf et al., Acta Neurol. Scand., vol. 88, 1993, pp. 97-99.
"Regulation of Tumor Necrosis Factor Expression in macrophage-like Cell Line by Lipopolysaccharide and cyclic AMP", S.M. Taffet et al., Cellular immunology, vol. 120, 1989, pp. 291-300.
"The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle", M.L. Reeves et al., Biochem J., vol. 241, 1987, pp. 535-541.
"Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1--but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats", O. Rott et al., Eur. J. Immunol., vol. 23, 1993, pp. 1745-1751.
"The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages", F.U. Schade and C. Schudt, Eur. J. Pharma., vol. 230, 1993, pp. 9-14.
"Multiple Sclerosis and Allied Demyelinative Diseases", Principles of Neurology, 1993, pp. 777-791.
Molnar-Kimber et al., Mediators of Inflammation, "Differential regulation of TNF.alpha.and II-1.beta.production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors" (1992).
Sharief et al., "Association Between Tumor Necrosis Factor-alpha . . .," new England J. of Med., 325(7):467-472, Aug. 15, 1991.
Benvenuto et al., "Increased Synthesis of Tumor Necrosis Factor . . ., " J. Neurol., 237(SUP1):83, 1990.
Kirby et al., "Prostacyclin Increases Cyclic-Nucleotide . . ., " The Lancet, 2(8192):453-454, Aug. 30, 1980.
Renz et al., "Release of Tumor Necrosis Factor-.alpha.From Macrophages . . ., " J. of Immunology, pp. 2388-2393, Oct. 1, 1988.
Strieter et al., "Cellular and Molecular Regulation of Tumor . . ., " Biochem. and Biophys. Research Comm., 155(3):1230-1236, Sep. 30, 1988.
Spengler et al., "Dynamics of Cyclic AMP- and Prostaglandin . . ., " Infectionand Immunity, 57(9):2837-2841, Sep. 1989.
Lloyd J. Old, "Tumor necrosis factor: Another chapter in the long . . ., " Nature, vol. 330, pp. 602-603, Dec. 17, 1987.
Miller et al., "Tumour Necrosis Factor in Bronchopulmonary . . ., " Lancet, vol. II for 1989, pp. 712-714, Sep. 23, 1989.
Tracey et al., "Anti-cachectin/TNF monoclonal antibodies prevent . . ., " Nature, vol. 330, pp. 662-664, Dec. 17, 1987.
Dezube et al., "Pentoxifylline and wellbeing in patients with cancer," Lancet, 335 (8690):662, Mar. 17, 1990.
Frolich et al., "In the Elevation of Cyclic . . ., " J. Invest. Dermat., 90(2):240, 1988.
Marivet et al., "Inhibition of Cyclic Adenosine-3', 5'-monophosphate . . ., " J., Med. Chem., 32:1450-1457, 1989.

Affiliated with

Also associated with

Rating

Treatment of multiple sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of multiple sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of multiple sclerosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2256910